Severity
Moderate
FDA Drug recall · Reported June 17, 2020
Subpotent drug - Product did not contain drug.
QuVa Pharma, Inc. recalled oxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium Chloride Injection for IV U… - a moderate-severity action.
oxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium Chloride Injection for IV U… was recalled by QuVa Pharma, Inc. in June 17, 2020. Reason: Subpotent drug - Product did not contain drug.. Check the official notice for the remedy. Verify recall #D-1302-2020 with the FDA Drug before acting.
The recall
QuVa Pharma, Inc. issued this moderate-severity FDA Drug recall-Subpotent drug - Product did not contain drug..
Sourced from official FDA Drug enforcement records. Verify recall #D-1302-2020 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1302-2020) was formally reported on June 17, 2020, with the manufacturer initiating the action on May 28, 2020. It is classified under Moderate severity (Class II), with a current status of Terminated. QuVa Pharma, Inc. is listed as the recalling firm, operating out of Sugar Land, TX. Federal records list the affected scope as 648 bags.
The documented reason for this recall is: Subpotent drug - Product did not contain drug. Distribution data in the federal record shows the product reached: USA Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
648 bags
Related Recalls
6
5 from same agency
oxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium Chloride Injection for IV Use, Rx only, QuVa Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478 888-339-0874, NDC 70092-1068-07
Subpotent drug - Product did not contain drug.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-1302-2020 |
| Date reported | June 17, 2020 |
| Date initiated | May 28, 2020 |
| Recalling firm | QuVa Pharma, Inc. |
| Firm location | Sugar Land, TX |
| Affected scope | 648 bags |
| Distribution | USA Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported June 17, 2020. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.